Cover Image
市場調查報告書

印度的醫藥品、醫療產業(季度更新報告)

India Pharmaceuticals and Healthcare Report Q2 2017

出版商 BMI Research 商品編碼 191492
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
印度的醫藥品、醫療產業(季度更新報告) India Pharmaceuticals and Healthcare Report Q2 2017
出版日期: 2017年03月01日 內容資訊: 英文 120 Pages
簡介

印度的醫藥品產業的收益規模,預計從2014年的160億美元,到2015年擴大11.7%,達到170億美元。還有醫療產業,預計從2014年的830億美元,到2015年成長12.4%,成為900億美元。

本報告提供印度的製藥、醫療產業結構和最新趨勢相關分析、今後10年的產業規模的動向估計、產業課題(風險)和未來商機(利潤)相關評估、政府的政策、規定、宏觀經濟環境、主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

  • 政治
  • 經濟
  • 業務風險

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用(OTC)醫藥品市場預測
  • 醫藥品的對外貿易情形
  • BMI的預測方案相關主要風險

宏觀經濟預測

  • 經濟分析

產業的風險/利潤、等級

  • 亞洲:風險/利潤、等級
  • 印度:風險/利潤、等級
    • 利潤
    • 風險

市場概況

產業的趨勢與發展

  • 流行病學
  • 醫療部門
  • 醫療部門的發展
  • 醫療保險
  • 研究開發(R&D)
  • 臨床實驗
  • 生技仿製藥
  • 傳統藥物

法規的發展

  • 醫藥品的廣告
  • 醫藥品安全性監視(藥物安全檢測)
  • 知識產權的保護體制
  • 價格政策
  • 強制許可證

競爭環境

  • 學名藥品產業
  • 產業的主要動向
  • 醫藥品的流通結構
  • 醫藥品的零售部門

企業簡介

  • Aurobindo Pharmaceutical
  • Cipla
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Ranbaxy Laboratories
  • Sanofi India
  • Sun Pharmaceutical

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 等級概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-1937

BMI View: India's demonetisation policy will accentuate the operational risks facing pharmaceutical firms operating in the country. Risks for the sector will be acute in the short term as the ban on largedenomination currency notes imposes payment barriers to patients in a market that is heavily reliant on out-of-pocket spending. The policy's full impact is expected to be more pronounced in the next few months with public hospitals and pharmacies ceasing to accept old INR500 (USD7.4) bills and advanced purchases by patients with chronic disease. Over the long term, the effects of the demonetisation policy on the broader economy represent the primary channel through which the measure can alter India's pharmaceutical sales growth trajectory.

Headline Expenditure Projections

  • Pharmaceuticals: INR1,1183bn (USD18bn) in 2016 to INR1,310bn (USD19bn) by 2017; +10.7% in local currency terms and 8.8% in US dollar terms.
  • Healthcare: INR7,550bn (USD113bn) in 2016 to INR8,521bn (USD125bn) by 2017; +12.9% in local currency terms and 10.9% in US dollar terms.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (India 2015-2021)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (India 2013-2021)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (India 2013-2021)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (India 2013-2021)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (India 2013-2021)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (India 2013-2021)
  • Patented Drug Market Forecast
    • Table: Selected Patent Developments Affecting Drugmakers
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (India 2013-2021)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (India 2013-2021)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (India 2013-2021)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (India 2015-2021)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (India 2015-2021)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index
  • India Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
    • Table: History Of The Indian Patent System
    • Table: Special 301 Submission: Issues Raised For India
    • Table: A Series Of Setbacks For Innovative Pharmaceutical Firms
  • Pricing Regime

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (India 2011-2016)
    • Table: Healthcare Personnel (India 2011-2016)
    • Table: Healthcare Activity (India 2011-2016)
  • Research & Development
    • Clinical Trials
    • Epidemiology
      • Table: Estimated Number Of New Cases Of Cancer In India

Competitive Landscape

  • Research-Based Industry
    • Table: Ordinary Members Of OPPI
    • Table: Multinational Market Activity
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector

Company Profile

  • Aurobindo Pharmaceutical
  • Cipla
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi India
  • Sun Pharmaceutical

Demographic Forecast

  • Table: Population Headline Indicators (India 1990-2025)
  • Table: Key Population Ratios (India 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (India 1990-2025)
  • Table: Population By Age Group (India 1990-2025)
  • Table: Population By Age Group % (India 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top